Topic: obesity treatments
Rhythm plans to complete a rolling submission to the FDA around the end of the year, positioning it to bring the drug to market in 2020.
The decision is another blow for Hanmi, which lost a $690 million deal with Eil Lilly in January and will now forego up to $810 million from J&J.
An enzyme that works on leptin receptors and a receptor protein called MC3R could be anti-obesity drug targets.
The round equips Gelesis to get its manufacturing and commercial arms ready for launch should regulators look favorably on its mixed late-phase data.
Scientists at Yale believe they’ve found an immune connection to the inability to burn belly fat—and a possible solution.
More than half of subjects who took the hydrogel particles lost weight, encouraging Gelesis to file for approval despite missing another endpoint.
The deal gives Boehringer access to Gubra’s expertise in the design, synthesis and preclinical testing of therapeutic peptides.
Allurion Technologies has raised $27 million in series C funding for its swallowable, procedureless, weight-loss balloon.
Scientists at Beth Israel Deaconess Medical Center are discovering why the process of feeling too full to eat any more goes awry in some people.
Less than a year ago, Zafgen was poleaxed by the failure of its lead weight-loss drug beloranib, shedding staff as its share price tumbled. Now, the Boston biotech is back with the first data on a follow-up it hopes will put it back on track.